Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Advertisement

British Journal of Cancer
  • View all journals
  • Search
  • My Account Login
  • Content Explore content
  • About the journal
  • Publish with us
  • Sign up for alerts
  • RSS feed
  1. nature
  2. british journal of cancer
  3. regular article
  4. article
Adjuvant high-dose medroxyprogesterone acetate for early breast cancer: 13 years update in a multicentre randomized trial
Download PDF
Download PDF
  • Regular Article
  • Open access
  • Published: 03 July 2001

Adjuvant high-dose medroxyprogesterone acetate for early breast cancer: 13 years update in a multicentre randomized trial

  • C Focan1,
  • M Beauduin2,
  • E Salamon3,
  • J de Greve4,
  • G de Wasch4,
  • J P Lobelle5,
  • F Majois2,
  • A Tagnon6,
  • J Tytgat7,
  • S van Belle8,
  • R Vandervellen9 &
  • A Vindevoghel3
  • for the Adjuvant Breast Cancer Project Belgium

British Journal of Cancer volume 85, pages 1–8 (2001)Cite this article

  • 1823 Accesses

  • 17 Citations

  • Metrics details

This article has been updated

Abstract

The authors updated their report on a randomized trial initiated in 1982 comparing, in early breast cancer, high-dose IM Medroxyprogesterone acetate (HD-MPA) adjuvant hormonotherapy during 6 months with no hormonotherapy; node-positive patients also received 6 courses of IV CMF (day 1, day 8; q.4 weeks). 246 node-negative (NN) and 270 node-positive (NP) patients had been followed for a median duration of 13 years. Previous results were confirmed in this analysis on mature data. In NN patients, relapse-free survival (RFS) was improved in the adjuvant hormonotherapy arm, regardless of age while overall survival (OAS) was also increased in younger (less then 50 years) patients. In the whole group of NP patients, no difference was seen regarding RFS or OAS. However, an age-dependant opposite effect was observed: younger patients (< 50) experienced a worse and significant outcome of relapse-free and overall survivals when receiving adjuvant HD-MPA while older patients (> = 50) enjoyed a significant improvement of their relapse-free survival. For both NN and NP patients, differences in overall survivals observed in older women with a shorter follow-up, were no longer detected. © 2001 Cancer Research Campaign http://www.bjcancer.com

Similar content being viewed by others

Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial

Article Open access 21 June 2023

A population‑based propensity score matching analysis of neoadjuvant compared to adjuvant chemotherapy in luminal breast cancer

Article Open access 20 March 2025

Extended adjuvant endocrine therapy in a longitudinal cohort of young breast cancer survivors

Article Open access 25 April 2023

Article PDF

Change history

  • 16 November 2011

    This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication

References

  • Alberts SR, Ingle JN, Roche PR, Cha S, Wold LE, Favr GH Jr, Knook JE and Wieand HS (1996) Comparison of estrogen receptor determination by a biochemical ligand binding assay and immunohistochemical staining with monoclonal antibody ER1D5 in females with lymph node positive breast carcinoma entered on prospective clinical trials. Cancer 78: 764–772

    Article  CAS  Google Scholar 

  • Andersen J (1992) Determination of estrogen receptors in paraffin-embedded tissue. Technic and the value in breast cancer treatment. Acta Oncol 31: 611–627

    Article  CAS  Google Scholar 

  • Andersson M, Kamby C, Jensen MB, Mouridsen H, Ejlerstsen B, Dombernowsky P, Rose C, Cold S, Overgaard M, Andersen J and Kjaer M (1999) Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy. Report from the Danish Breast Cancer Co-operative Group DBCG 82B Trial. Eur J Cancer 35: 1659–1666

    Article  CAS  Google Scholar 

  • Beex L, Burghouts J, van Turnhout J, Breed W, Hillen H, Holdrinet A, Boetius G, Hoogendoorn G, Doesburg W and Verhulst M (1987) Oral versus i.m. administration of high-dose medroxyprogesterone acetate in pretreated patients with advanced breast cancer. Cancer Treat Rep 71: 1151–1156

    CAS  PubMed  Google Scholar 

  • Blossey HC, Wander HE, Koebberling J and Nagel GA (1984) Pharmacokinetic and pharmacodynamic basis for the treatment of metastatic breast cancer with high-dose medroxyprogesterone acetate. Cancer 54: 1208–1215

    Article  CAS  Google Scholar 

  • Bramwell VHC and Pritchard KI (1999) Tamoxifen added to adjuvant chemotherapy in premenopausal women with early breast cancer: is it standard practice or still a subject for study?. Eur J Cancer 35: 1625–1627

    Article  CAS  Google Scholar 

  • Canney PA, Dowsett M and Priestman TJ (1988) The pharmacokinetics of medroxyprogesterone acetate following two different loading dose schedules in advanced carcinoma of the breast. Br J Cancer 58: 73–76

    Article  CAS  Google Scholar 

  • Castiglione-Gertsch M, Pampallona S, Varini M, Cavalli F, Brunner K, Senn HJ, Goldhirsch A and Metzger U (1993) Primary endocrine therapy for advanced breast cancer: to start with tamoxifen or with medroxyprogesterone acetate?. Ann Oncol 4: 735–740

    Article  CAS  Google Scholar 

  • Cavalli F, Goldhirsch A, Jungi F, Martz G, Mermillod B and Alberto P (for the Swiss Group for Clinical Cancer Research) (1984) Randomized trial of low-versus high-dose medroxyprogesterone-acetate in the induction treatment of postmenopausal patients with advanced breast cancer. J Clin Oncol 2: 414–419

    Article  CAS  Google Scholar 

  • Cox DR (1972) Regression models and life-tables (with discussion). J. R. Stat S [B] 34: 187–220

    Google Scholar 

  • Early Breast Cancer Trialists’ Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. The Lancet 351: 1451–1467

  • Early Breast Cancer Trialists’ Collaborative Group (1996) Ovarian ablation in early breast cancer: overview of the randomised trials. The Lancet 348: 1189–1199

  • Ejlertsen B, Dombernowsky P, Mouridsen HT, Kamby C, Kjaer M, Rose C, Andersen KW, Jensen MB, Bengtsson NO and Bergh J (1999) Comparable effect of ovarian ablation (OA) and CMF chemotherapy in premenopausal hormone receptor positive breast cancer patients (PRP). Proc of ASCO 18: 660 (abstr. 248)

    Google Scholar 

  • Etienne MC, Milano G, Frenay M, Renee N, François E, Thyss A, Schneider M and Namer M (1992) Pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate in advanced breast cancer patients. J Clin Oncol 1992 10: 1176–1182

    CAS  Google Scholar 

  • Fisher B, Dignam J, Wolmark N, DeCillis A, Emir B, Wickerham DL, Bryant J, Dimitrov NV, Abramson N, Atkins JN, Shibata H, Deschenes L and Margolese RG (1997) Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 89: 1673–1682

    Article  CAS  Google Scholar 

  • Focan C, Baudoux A, Beauduin M, Bunescu U, Dehasque N, Dewasch G, Lobelle JP, Longeval E, Majois F, Salamon E, Spapen H, Tagnon A, Tytgat J, Van Belle S, Vanderlinden B, Vandervellen R and Vindevoghel A (1986) Improvement of hematological and general tolerance to CMF by high-dose medroxyprogesterone-acetate (HD-MPA) adjuvant treatment for primary node positive breast cancer (analysis of 100 patients). Anticancer Res 6: 1095–1100

    CAS  PubMed  Google Scholar 

  • Focan C, Baudoux A, Beauduin M, Bunescu U, Dehasque N, Dewasch G, Lobelle JP, Longeval E, Majois F, Mazy V, Nickers P, Salamon E, Tagnon A, Tytgat J, van Belle S, Vanderlinden B, Vandervellen R and Vindevoghel A (1989) Adjuvant treatment with high dose medroxyprogesterone-acetate in node-negative early breast cancer. A 3-year interim report on a randomized trial. Acta Oncologica 28: 237–250

    Article  CAS  Google Scholar 

  • Focan C, Beauduin M, Salamon E, De Wasch G, Driesschaert P, Lobelle JP, Longeval E, Majois F, Tagnon A, Tytgat J, Van Belle S, Vanderlinden B, Vanderhoven P, Vandervellen R, Vindevoghel A and Warnier A (1990). Influence of age, node involvement and CMF chemotherapy on the outcome of early breast cancer treated with high dose medroxyprogesterone acetate (HD-MPA) as adjuvant hormonotherapy: 5 years Results of a randomized trial, in SE Salmon (ed): Adjuvant Therapy of Cancer VI. pp 319–329

  • Focan C, Beauduin M, Salamon E, De Grève J, De Wasch G, Lobelle JP, Majois F, Tagnon A, Tytgat J, van Belle S, Vandervellen R and Vindevoghel A (1995) High-dose medroxyprogesterone acetate as adjuvant hormonotherapy in early breast cancer: 9 years results of a multicenter randomized trial. In Jonat W, Kaufmann M, Munk K (eds): Hormone-Dependent Tumors. Basic Research and Clinical Studies, vol 50, pp 145–158. Contrib Oncol. Basel, Karger

    Google Scholar 

  • Focan C, Beauduin M, Salamon E, De Gréve J, De Wasch G, Lobelle JP, Majois F, Tagnon A, Tytgat J, van Belle S, Vandervellen R and Vindevoghel A (1996) High dose medroxyprogesterone acetate (HD-MPA) as adjuvant hormonotherapy for early breast cancer. Ten years results of a multicenter randomized trial. Acta Clin Belgica, 51 3: 194

    Google Scholar 

  • Gill PG, Gebski V, Snyder R, Burns I, Levi J, Byrne M and Coates A (1993) Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment of response and survival in patients with metastatic breast cancer. Ann Oncol 4: 741–744

    Article  CAS  Google Scholar 

  • Hryniuk WM and Levine MN (1986) Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 4: 1162–1170

    Article  CAS  Google Scholar 

  • Hupperets PSGJ, Wils J, Volovics L, Schouten L, Fickers M, Bron H, Schouten H, Jager J, de Jong J and Beex L (1993) Adjuvant chemo-hormonal therapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) with or without medroxyprogesterone acetate for node-positive breast cancer patients. Update at 7 year follow-up. Ann Oncol 4: 295–301

    Article  CAS  Google Scholar 

  • Hutchins L, Green S, Ravdin P, Lew D, Martino S, Abeloff M, Lyss A, Henderson C, Alfred C, Dakhil S, Pierce J, Goodwin W, Caton J, Rivkin S, Chapman R and Osborne K (1999) CMF versus CAF +/– Tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node negative patients: update of tamoxifen results. Breast Cancer Research and Treatment 57: 25

    Google Scholar 

  • Hyder SM, Murthy L and Stacel GM (1998) Progestin regulation of vascular endothelial growth factor in human breast cancer cells. Cancer Res 58: 392–395

    CAS  Google Scholar 

  • Jakesz R, Hausmaninger H, Samonigg H, Kubista E, Depisch D, Fridrik M, Stierer M, Gnant M, Steger G, Kolb R, Jatzko G, Hofbauer F, Reiner G and Luschin-Ebengreuth G (1999) Comparison of adjuvant therapy with tamoxifen and goserelin vs CMF in premenopausal stage I and II hormone-responsive breast cancer patients: Four-year results of Austrian breast cancer study group (ABCSG) trial 5. Proc of ASCO 18: abstr. 250

    Google Scholar 

  • Kaplan EL and Meier P (1958) Non parametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481

    Article  Google Scholar 

  • Löber J, Rose C, Salimtschik M and Mouridsen HT (1981) Treatment of advanced breast cancer with progestins. Acta Obstet Gynecol Scand (suppl 101) 39–46

    Article  Google Scholar 

  • Martoni A, Longhi A, Canova N and Pannuti F (1991) High-dose medroxyprogesterone acetate versus oophorectomy as first-line therapy of advanced breast cancer in premenopausal patients. Oncology 48: 1–6

    Article  CAS  Google Scholar 

  • Mattsson W (1980). A phase III trial of treatment with tamoxifen versus treatment with high-dose medroxyprogesterone-acetate in advanced post-menopausal breast cancer, in lacobelli S and di Marco A (ed): Role of medroxyprogesterone in endocrine-related tumors – Progress in cancer research and therapy,

  • Muss HB, Case LD, Capizzi RL, Cooper MR, Cruz J, Jackson D, Richards F, Powell BL, Spurr CL and White D (1990) High-versus standard-dose megestrol acetate in women with advanced breast cancer. A phase III trial of the Piedmont Oncology Association. J Clin Oncol 8: 1797–1805

    Article  CAS  Google Scholar 

  • Muss HB, Wells B, Paschold EH, Black WR, Coopper MR, Capizzi RL, Christian R, Cruz JM, Jackson DV and Powell BL (1988) Megestrol acetate versus tamoxifen in advanced breast cancer: 5 year analysis – a phase III trial of the Piedmont Oncology Association. J Clin Oncol 6: 1098–1106

    Article  CAS  Google Scholar 

  • Ng V, Ragaz J, Spinelli HJ and Jackson S (1989) Introduction of cumulative dose intensity product (DIP) for measuring the delivered dose intensity (DI) of chemotherapy – Analysis of the British Columbia Breast Cancer Randomized Study. Proceedings of Am Soc Clin Oncol 8: 47 (Abstr 181)

    Google Scholar 

  • Pannuti F, Martoni A, Cilenti G, Camaggi CM and Fruet F (1988) Adjuvant therapy for operable breast cancer with medroxyprogesterone acetate alone in postmenopausal patients or in combination with CMF in premenopausal patients. Eur J Cancer Clin Oncol 24: 423–429

    Article  CAS  Google Scholar 

  • Paridaens R, Becquart D, Michel J, Vanderlinden B, Longueville J, Majois F, Beauduin M, Focan C, Wildiers J, Bernheim J, Lobelle JP, Arrigo C, Sylvester RJ and Heuson JC (1986) Oral versus intramuscular high-dose medroxyprogesterone (HD-MPA) in advanced breast cancer. Anticancer Res 6: 1089–1094

    CAS  PubMed  Google Scholar 

  • Pertschuk LP, Kim YD, Axiotis CA, Braverman AS, Carter AC, Eisenberg KB and Braithwaite LV (1994) Estrogen receptor immunocytochemistry: the promise and the perils. J Cell Biochem Suppl 19: 134–137

    CAS  PubMed  Google Scholar 

  • Robustelli Della Cuna G, Calciati A, Bernardo Strada MR, Bumma C and Campio L (1980). High-dose medroxyprogesterone-acetate (HD-MPA) combined with chemotherapy for metastatic breast carcinoma, in lacobelli S, Di Marco A (ed): Role of medroxyprogesterone acetate in endocrine-related tumors, pp 53–64,

  • Rubens RD (1993) Towards improved endocrine therapy for advanced breast cancer. Ann Oncol 4: 712–713

    Article  CAS  Google Scholar 

  • Rutqvist LE (1999). Zoladex and tamoxifen as adjuvant therapy in premenopausal breast cancer: a randomised trial by the cancer research campaign (C.R.C.) Breast Cancer Trials Group, the Stockholm Breast Cancer Study Group, The South-East Sweden Breast Cancer Group & the Gruppo Interdisciplinare Valutazione Interventi in Oncologica (G.I.V.I.O.), Proc of ASCO ASCO, vol. 18, 67a (abstr. 251).

  • Stewart HJ and Everington D (1995) Ovarian ablation versus CMF chemotherapy as adjuvant therapy for breast cancer. In Jonat W, Kaufmann M, Munk K (eds): Hormone-Dependent Tumors. Basic Research and Clinical Studies. Vol 50, pp 176–183 Contrib Oncol. Basel, Karger

    Google Scholar 

  • Tamassia V, Battaglia A, Gangina F, Isetta AM, Sacchetti G, Cavalli F, Goldhirsch A, Brunner K, Bernardo G and Robustelli della Cuna G (1982) Pharmacokinetic approach to the selection of dose schedules for medroxyprogesterone-acetate in clinical oncology. Cancer Chemother Pharmacol 8: 151–156

    Article  CAS  Google Scholar 

  • Tchekmedyian NS, Tait N and Aisner J (1986) High-dose megestrol acetate in the treatment of postmenopausal women with advanced breast cancer. Semin Oncol 13: 20–25

    CAS  PubMed  Google Scholar 

  • Van Veelen H, Willemse PH, Sleijfer DT, Sluiter WJ and Doorenbos H (1985) Endocrine effects of medroxyprogesterone acetate: relation between plasma level and suppression of adrenal steroids in patients with breast cancer. Cancer Treat Rep 69: 979–983

    Google Scholar 

  • Van Veelen H, Willemse PHB, Tabies T, Sleijfer DT, Sluiter WJ and Doorenbos J (1986) Oral high-dose medroxyprogesterone acetate versus tamoxifene. A randomized cross-over trial in postmenopausal patients with advanced breast cancer. Cancer 58: 7–13

    Article  CAS  Google Scholar 

  • Wils JA (1988) Myeloprotective effect of high dose medroxyprogesterone acetate (MPA). Chemioterapia 7: 60–62

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Saint-Joseph Clinics, Liège, Belgium

    C Focan

  2. Jolimont Hospital , Haine Saint-Paul, Belgium

    M Beauduin & F Majois

  3. Sainte-Elisabeth Clinic, Namur, Belgium

    E Salamon & A Vindevoghel

  4. Oncology Centre, AZ-VUB, Jette, Belgium

    J de Greve & G de Wasch

  5. Pharmacia & Upjohn, Benelux, Brussels, Belgium

    J P Lobelle

  6. Institut Medico-Chirurgical, Tournai, Belgium

    A Tagnon

  7. Heilige Hart Clinic, Roeselaere, Belgium

    J Tytgat

  8. Oncology Centre University, Gent, Belgium

    S van Belle

  9. Saint-Michel Clinic , Brussels, Belgium

    R Vandervellen

Authors
  1. C Focan
    View author publications

    Search author on:PubMed Google Scholar

  2. M Beauduin
    View author publications

    Search author on:PubMed Google Scholar

  3. E Salamon
    View author publications

    Search author on:PubMed Google Scholar

  4. J de Greve
    View author publications

    Search author on:PubMed Google Scholar

  5. G de Wasch
    View author publications

    Search author on:PubMed Google Scholar

  6. J P Lobelle
    View author publications

    Search author on:PubMed Google Scholar

  7. F Majois
    View author publications

    Search author on:PubMed Google Scholar

  8. A Tagnon
    View author publications

    Search author on:PubMed Google Scholar

  9. J Tytgat
    View author publications

    Search author on:PubMed Google Scholar

  10. S van Belle
    View author publications

    Search author on:PubMed Google Scholar

  11. R Vandervellen
    View author publications

    Search author on:PubMed Google Scholar

  12. A Vindevoghel
    View author publications

    Search author on:PubMed Google Scholar

Consortia

for the Adjuvant Breast Cancer Project Belgium

Rights and permissions

From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/

Reprints and permissions

About this article

Cite this article

Focan, C., Beauduin, M., Salamon, E. et al. Adjuvant high-dose medroxyprogesterone acetate for early breast cancer: 13 years update in a multicentre randomized trial. Br J Cancer 85, 1–8 (2001). https://doi.org/10.1054/bjoc.2001.1829

Download citation

  • Received: 23 February 2000

  • Revised: 02 October 2000

  • Accepted: 09 February 2001

  • Published: 03 July 2001

  • Issue date: 06 July 2001

  • DOI: https://doi.org/10.1054/bjoc.2001.1829

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

This article is cited by

  • Reproductive epidemiology of glial tumors may reveal novel treatments: high-dose progestins or progesterone antagonists as endocrino-immune modifiers against glioma

    • Meric A. Altinoz
    • Aysel Ozpinar
    • Ilhan Elmaci

    Neurosurgical Review (2019)

  • Learning therapeutic lessons from metastasis suppressor proteins

    • Steven Christopher Smith
    • Dan Theodorescu

    Nature Reviews Cancer (2009)

  • Clinical-translational strategies for the elevation of Nm23-H1 metastasis suppressor gene expression

    • Jean-Claude Marshall
    • Jong Heun Lee
    • Patricia S. Steeg

    Molecular and Cellular Biochemistry (2009)

  • The progestational and androgenic properties of medroxyprogesterone acetate: gene regulatory overlap with dihydrotestosterone in breast cancer cells

    • Radhika P Ghatge
    • Britta M Jacobsen
    • Kathryn B Horwitz

    Breast Cancer Research (2005)

  • Menopausal hormone therapy after breast cancer

    • Graham A Colditz

    Breast Cancer Research (2005)

Download PDF

Advertisement

Explore content

  • Research articles
  • Reviews & Analysis
  • News & Comment
  • Current issue
  • Collections
  • Follow us on Twitter
  • Sign up for alerts
  • RSS feed

About the journal

  • Journal Information
  • Open access publishing
  • About the Editors
  • Contact
  • Special Issues
  • For Advertisers
  • Subscribe

Publish with us

  • For Authors & Referees
  • Language editing services
  • Open access funding
  • Submit manuscript

Search

Advanced search

Quick links

  • Explore articles by subject
  • Find a job
  • Guide to authors
  • Editorial policies

British Journal of Cancer (Br J Cancer)

ISSN 1532-1827 (online)

ISSN 0007-0920 (print)

nature.com sitemap

About Nature Portfolio

  • About us
  • Press releases
  • Press office
  • Contact us

Discover content

  • Journals A-Z
  • Articles by subject
  • protocols.io
  • Nature Index

Publishing policies

  • Nature portfolio policies
  • Open access

Author & Researcher services

  • Reprints & permissions
  • Research data
  • Language editing
  • Scientific editing
  • Nature Masterclasses
  • Research Solutions

Libraries & institutions

  • Librarian service & tools
  • Librarian portal
  • Open research
  • Recommend to library

Advertising & partnerships

  • Advertising
  • Partnerships & Services
  • Media kits
  • Branded content

Professional development

  • Nature Awards
  • Nature Careers
  • Nature Conferences

Regional websites

  • Nature Africa
  • Nature China
  • Nature India
  • Nature Japan
  • Nature Middle East
  • Privacy Policy
  • Use of cookies
  • Legal notice
  • Accessibility statement
  • Terms & Conditions
  • Your US state privacy rights
Springer Nature

© 2026 Springer Nature Limited